Challenges in Antigenic Characterization of Circulating Influenza A(H3N2) Viruses during the 2011-2012 Influenza Season: an Ongoing Problem?

Kossyvakis, Athanasios; Pogka, Vasiliki; Melidou, Angeliki; Moutousi, Afroditi; Kalliaropoulos, Antonios; Exindari, Maria; Emmanouil, Mary; Horefti, Elina; Spala, G; Meijer, Adam; Malisiovas, Nikolaos; Mentis, Αndreas

doi:10.1128/jcm.03236-14

Cited by 11 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in our data, A(H3N2) viruses were slightly overrepresented among those selected for characterisation (16% vs 10% for all subtypes). A(H3N2) viruses have proved difficult to characterise antigenically in recent years [ 19 ] and therefore greater effort has been put into their characterisation.…”

Section: Discussionmentioning

confidence: 99%

Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14

et al. 2016

Self Cite

View full text Add to dashboard Cite

Influenza antigenic and genetic characterisation data are crucial for influenza vaccine composition decision making. Previously, aggregate data were reported to the European Centre for Disease Prevention and Control by European Union/European Economic Area (EU/EEA) countries. A system for collecting case-specific influenza antigenic and genetic characterisation data was established for the 2013/14 influenza season. In a pilot study, 11 EU/EEA countries reported through the new mechanism. We demonstrated feasibility of reporting strain-based antigenic and genetic data and ca 10% of influenza virus-positive specimens were selected for further characterisation. Proportions of characterised virus (sub)types were similar to influenza virus circulation levels. The main genetic clades were represented by A/StPetersburg/27/2011(H1N1)pdm09 and A/Texas/50/2012(H3N2). A(H1N1)pdm09 viruses were more prevalent in age groups (by years) < 1 (65%; p = 0.0111), 20–39 (50%; p = 0.0046) and 40–64 (55%; p = 0.00001) while A(H3N2) viruses were most prevalent in those ≥ 65 years (62%*; p = 0.0012). Hospitalised patients in the age groups 6–19 years (67%; p = 0.0494) and ≥ 65 years (52%; p = 0.0005) were more frequently infected by A/Texas/50/2012 A(H3N2)-like viruses compared with hospitalised cases in other age groups. Strain-based reporting enabled deeper understanding of influenza virus circulation among hospitalised patients and substantially improved the reporting of virus characterisation data. Therefore, strain-based reporting of readily available data is recommended to all reporting countries within the EU/EEA.

show abstract

Section: Discussionmentioning

confidence: 99%

Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…S4). The genetic groups were assigned according to the WHO influenza virus clade classification (Barr et al, 2014;Klimov et al, 2012;Kossyvakis et al, 2015).…”

Section: Resultsmentioning

confidence: 99%

Predicting clinical severity based on substitutions near epitope A of influenza A/H3N2

Lee

Tang

Loh

et al. 2015

Infection, Genetics and Evolution

View full text Add to dashboard Cite

“…All specimens were analysed to assess the quality of the specimen and extraction procedure, as well as for the presence of influenza virus by real‐time RT‐PCR with primers and probes as described in WHO molecular diagnostic protocols . Aghia Sophia samples were analysed at the Hellenic Pasteur Institute using NucliSENS® easyMAG® platforms (bioMérieux Hellas) and an in‐house multiplex real‐time RT‐PCR. The PCR protocol is validated according to ISO 15189 requirements and deposited with the European Influenza Surveillance Network .…”

Section: Methodsmentioning

confidence: 99%

“…The mean Risk-adjusted ViVI Score was 8.29 (SD 4.56; range 0-32), while the median (IQR) was 7.5 (5)(6)(7)(8)(9)(10). Figure 3A,B…”

Section: Risk-adjusted Vivi Score: a New Score Based On Disease Sevmentioning

confidence: 98%

See 1 more Smart Citation

Partnering for enhanced digital surveillance of influenza‐like disease and the effect of antivirals and vaccines (PEDSIDEA)

Rath

Maltezou

Papaevangelou

et al. 2019

Influenza Resp Viruses

View full text Add to dashboard Cite

Background Standardised clinical outcome measures are urgently needed for the surveillance of influenza and influenza‐like illness (ILI) based on individual patient data (IPD). Objectives We report a multicentre prospective cohort using a predefined disease severity score in routine care. Patients/Methods The Vienna Vaccine Safety initiative (ViVI) Disease Severity Score (“ViVI Score”) was made available as an android‐based mobile application to three paediatric hospitals in Berlin and Athens between 2013 and 2016. Healthcare professionals assessed ILI patients at the point of care including severity, risk factors and use of antibiotics/antivirals/vaccines. RT‐PCR for influenza A/B viruses was performed at the Hellenic Pasteur Institute and the Robert Koch Institute. PCR testing was blinded to severity scoring and vice versa. Results A total of 1615 children aged 0‐5 years (54.4% males) were assessed at the three sites. The mean age was 1.7 years (SD 1.5; range 0‐5.9). The success rate (completion of the scoring without disruption to the ER workflow) was 100%. ViVI Disease Severity Scores ranged from 0 to 35 (mean 13.72). Disease severity in the Berlin Cohort was slightly higher (mean 15.26) compared to the Athens Cohorts (mean 10.86 and 11.13). The administration of antibiotics was most prevalent in the Berlin Cohort, with 41.2% on antibiotics (predominantly cefuroxime) as opposed to only 0.5% on neuraminidase inhibitors. Overall, Risk‐adjusted ViVI Scores were significantly linked to the prescription of both, antibiotics and antivirals. Conclusions The Risk‐adjusted ViVI Score enables a precision medicine approach to managing ILI in multicentre settings. Using mobile applications, severity data will be obtained in real time with important implications for the evaluation of antiviral/vaccine use.

show abstract

Challenges in Antigenic Characterization of Circulating Influenza A(H3N2) Viruses during the 2011-2012 Influenza Season: an Ongoing Problem?

Abstract: Genetic and antigenic characterization of 37 representative influenza A(H3N2) virus strains isolated in

Cited by 11 publications

References 22 publications

Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14

Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14

Predicting clinical severity based on substitutions near epitope A of influenza A/H3N2

Partnering for enhanced digital surveillance of influenza‐like disease and the effect of antivirals and vaccines (PEDSIDEA)

Contact Info

Product

Resources

About